Clinical Trial Update: Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract [Phase 4]

View source ↗

Summary

Phase 4 trial update on IARULIL® for recurrent cystitis refractory to Escherichia coli extract; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystitis

Drugs mentioned

• IARULIL®

Snippet

Sponsor: Samsung Medical Center | Conditions: Recurrent Cystitis | Phase 4 | Status: COMPLETED